We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

160 hedge funds and large institutions have $1.82B invested in Portola Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 64 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 13

94% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 33

92% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $848K

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

44% more capital invested

Capital invested by funds: $1.26B → $1.82B (+$556M)

20% more funds holding

Funds holding: 133160 (+27)

Holders
160
Holders Change
+27
Holders Change %
+20.3%
% of All Funds
4.26%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
41
Increased
64
Reduced
33
Closed
13
Calls
$1.62M
Puts
$848K
Net Calls
+$776K
Net Calls Change
+$386K
Name Holding Trade Value Shares
Change
Change in
Stake
MCM
76
Mazama Capital Management
Oregon
$1.64M -$934K -27,192 -39%
Bank of America
77
Bank of America
North Carolina
$1.59M +$1.25M +36,460 +661%
RhumbLine Advisers
78
RhumbLine Advisers
Massachusetts
$1.55M +$264K +7,695 +23%
BA
79
BlackRock Advisors
Delaware
$1.52M +$620K +18,054 +82%
ARTA
80
A.R.T. Advisors
New York
$1.5M +$1.36M +39,633 New
HI
81
HBK Investments
Texas
$1.46M +$1.32M +38,319 New
3NC
82
300 North Capital
California
$1.44M +$6.22K +181 +0.5%
GL
83
GLG LLC
New York
$1.39M +$1.26M +36,668 New
D.E. Shaw & Co
84
D.E. Shaw & Co
New York
$1.37M +$238K +6,941 +24%
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
$1.34M +$71.9K +2,092 +6%
CC
86
CQS Cayman
Cayman Islands
$1.33M -$515K -15,000 -30%
WSA
87
Wall Street Associates
California
$1.33M -$24K -700 -2%
USAA
88
United Services Automobile Association
Texas
$1.22M +$63.2K +1,840 +6%
American Century Companies
89
American Century Companies
Missouri
$1.2M -$114K -3,308 -9%
Neuberger Berman Group
90
Neuberger Berman Group
New York
$1.15M +$284K +8,281 +38%
TRSOTSOK
91
Teachers Retirement System of the State of Kentucky
Kentucky
$1.06M
TI
92
Trexquant Investment
Connecticut
$998K +$903K +26,300 New
DA
93
DSC Advisors
Illinois
$949K +$859K +25,000 New
SGH
94
Sivik Global Healthcare
Connecticut
$949K +$859K +25,000 New
AA
95
ALPS Advisors
Colorado
$918K +$831K +24,195 New
DekaBank Deutsche Girozentrale
96
DekaBank Deutsche Girozentrale
Germany
$865K -$92.7K -2,700 -11%
QSS
97
Quantitative Systematic Strategies
Florida
$819K +$733K +21,342 New
VOYA Investment Management
98
VOYA Investment Management
Georgia
$763K
HCM
99
Highbridge Capital Management
New York
$706K -$1.39M -40,428 -68%
RIL
100
Rothschild Investment LLC
Illinois
$650K -$27.3K -796 -4%

PTLA Hedge Fund Activity: Q1 2015 in Review

160 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2015, worth a combined $1.82B — up 44% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PTLA positions and 13 closed out — a net gain of 28 holders — while 64 added to existing stakes and 33 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $23.2M. The largest seller was Abingworth, cutting an estimated $20M.

  • 160 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2015, up from 133 in Q4 2014.
  • Funds reported $1.82B of Portola Pharmaceuticals, Inc. stock for Q1 2015, up 44% quarter-over-quarter.
  • 41 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2015 and 13 closed out, a net change of +28 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q1 2015 was Wellington Management Group, an estimated $23.2M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q1 2015 was Abingworth, an estimated $20M sold.

Based on aggregated 13F filings for Q1 2015.